Interview with Ulf Schneider, Managing Partner, RUSSIA CONSULTING
You founded this business in 2003, and it has since grown to encompass five offices and over 250 experts. Can you tell our readers a bit about the history behind…
Address: 3А, Nagatinskaya Str., Moscow, 117105, Russia
Tel: +7 (495) 231-42-53
Web: http://www.arfp.ru/
The Association of the Russian pharmaceutical manufactures (ARPM) was established in 2002 as a non-commercial partnership bringing together leading Russian pharmaceutical companies. Currently their share in the local market makes more than 60% of medicine produced in Russia, more than 35% of export, and more than 70% of medicine of the domestic manufactures in the DLO/ONLS programme.
The ARPM mission is to develop the Russian pharmaceutical industry for the purpose of providing the population of Russia with modern, high-quality and affordable medicines.
The ARPM actively cooperates with Russian legislative and executive bodies. The ARPM is the member of Russian Chamber of Commerce and Industry.
The ARPM is the winner of the open competition of the professionals of the pharmaceutical market «Platinum Uncia» in the nomination «Public organization» in 2007.
Currently the ARPM unites about 20 pharmaceutical plants which are situated in all Russian regions: Moscow, St. Petersburg, Nizhniy Novgorod, the Urals, Siberia and the Far East.
You founded this business in 2003, and it has since grown to encompass five offices and over 250 experts. Can you tell our readers a bit about the history behind…
The following is an interview with Dr. Smirnov, as well as Dr. Dmitri Pavlovich, Director, Clinical Operations Russia Quintiles very recently announced the launch of its first commercial project in…
The following is an interview with Dr. Pavlovich, as well as Dr. Sergey Smirnov, Director, Business Development and Operations, CEE, CIS and Russia Quintiles very recently announced the launch of…
GSK CEO Andrew Witty has said that GSK must move away from selling “white pills in Western markets” in order to offset widespread generic erosion. This means diversifying the company’s…
The following is joint interview of Mr. Vayntrub and Regina Karymova, General Manager of Invar Mr. Vayntrub, you founded Invar in 1991, and began to capitalize on foreign investment in…
Pepeliaev, Goltsblat & Partners and the major UK firm Berwin Leighton Paisner (BLP). It calls itself the first international Russian law firm. Can you explain to our readers the rationale…
You have lead this company since its beginnings in 2003, when it acquired ICN pharmaceuticals. In 2007, Pharmstandard carried out an IPO of 43% of its shares. How has the…
You were working for GSK since 2003 before joining Galderma this year. Some within the industry might view Galderma as a step down from the third-ranked pharmaceutical company in the…
Janssen recently signed memorandums of understanding with both the Skolkovo Foundation and ChemRar. Can you describe the strategic parameters and intended outcomes of these agreements? How do they factor into…
Mr. Demidov, you are one of the pioneers of market research studies in Russia. There is a quote you like to use: ‘Market research is a business in the United…
How would you describe CMS’s own presence in the life sciences field in Russia, and what unique competitive advantages does the firm bring to this area of practice? Over the…
With the announcement of the Pharma 2020 strategy to develop the domestic pharmaceutical industry, multinational companies have pledged an excess of $1Bn in investment into local infrastructure. Servier, however, preempted…
See our Cookie Privacy Policy Here
